News
AVEO
15.00
0.00%
0.00
CORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee
Barchart · 03/28 14:22
AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee
Barchart · 03/25 07:10
AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial in The Oncologist
AVEO Oncology published a post-hoc analysis of long-term progression free survival, overall survival and safety data from the Phase 3 TIVO-3 trial. FOTIVDA (tivozanib) demonstrated a consistent safety profile in patients with advanced renal cell carcinoma.
Barchart · 02/06 07:10
More
Webull provides a variety of real-time AVEO stock news. You can receive the latest news about Aveo Pharma through multiple platforms. This information may help you make smarter investment decisions.
About AVEO
AVEO Pharmaceuticals, Inc. is an oncology-focused biopharmaceutical company. The Company is focused on delivering medicines for patients with cancer. The Company’s commercial product include FOTIVDA (tivozanib), which is an oral, vascular endothelial growth factor receptor (VEGFR) and tyrosine kinase inhibitor (TKI). The Company markets FOTIVDA (tivozanib) in the United States for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. It also develops FOTIVDA in immuno-oncology combinations in refractory RCC and other indications and has several other investigational programs in clinical development. The Company’s pipeline of product candidates includes ficlatuzumab, AV-380, AV-203 and AV-353. Its ficlatuzumab is a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor (HGF).